Cambridge, MA, United States of America

Frederick Joseph Schnell

USPTO Granted Patents = 10 

 

Average Co-Inventor Count = 2.0

ph-index = 2

Forward Citations = 9(Granted Patents)


Location History:

  • Cambridge, MA (US) (2020 - 2022)
  • Corvallis, OR (US) (2016 - 2023)

Company Filing History:


Years Active: 2016-2024

Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents

Title: Frederick Joseph Schnell: Innovating Antisense Oligomers

Introduction

Frederick Joseph Schnell, an innovative inventor based in Cambridge, MA, has made significant contributions to the field of biotechnology. With a remarkable portfolio of 10 patents, Schnell has focused primarily on developing methods and compounds that leverage antisense oligonucleotides for therapeutic applications.

Latest Patents

Schnell's latest patents highlight his pioneering work in the treatment of diseases associated with the acid alpha-glucosidase gene. One patent details modified antisense oligonucleotides that contain 10 to 40 nucleobases, designed to target a specific region within the intron 1 of the pre-mRNA of the human alpha glucosidase (GAA) gene. This innovative approach features a targeting sequence that includes additional nucleobases, enhancing the specificity and efficacy of the treatment. Another patent focuses on antisense oligomer compounds, also comprising 10 to 40 nucleobases that interact with target sequences to provide potential therapeutic benefits.

Career Highlights

Frederick Joseph Schnell has built a distinguished career while working at Sarepta Therapeutics, Inc. His research and development efforts have positioned him as a notable figure in the biotechnology industry, particularly in the advancement of RNA therapeutics. His commitment to innovation is evident in the successful navigation of complex scientific challenges, leading to several patented solutions that could impact various genetic disorders.

Collaborations

Throughout his career, Schnell has collaborated with talented individuals in the field, including Gunnar J Hanson and Richard Keith Bestwick. These partnerships have fostered an environment of shared knowledge and creativity, further driving advancements in the development of antisense therapies.

Conclusion

Frederick Joseph Schnell's work exemplifies the spirit of innovation in biotechnology. His patents on antisense oligonucleotides reflect a significant stride toward addressing genetic disorders, showcasing his ability to blend creativity with scientific rigor. As he continues to evolve within the industry, his contributions are sure to leave a lasting impact on therapeutic approaches for genetic diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…